AYTU BIOPHARMA, INC Form 10-Q/A: Amended quarterly report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-02-21: Form 10-Q/A; Period of report 2022-09-30; Description 10-Q/A; Document aytu-20220930x10qa.htm.
- 2019-05-14: Form 10-Q/A; Period of report 2018-12-31; Description AMENDMENT NO. 1; Document aytu_10q.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2023-02-21 | 10-Q/A | 2022-09-30 | 10-Q/A | aytu-20220930x10qa.htm |
| 2019-05-14 | 10-Q/A | 2018-12-31 | AMENDMENT NO. 1 | aytu_10q.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |